ALT

Altimmune, Inc. - Common Stock (ALT)

About Altimmune, Inc. - Common Stock (ALT)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Details

Daily high

$3.34

Daily low

$3.24

Price at open

$3.31

52 Week High

$6.44

52 Week Low

$2.56

Market cap

632.2M

Dividend yield

Volume

3.5M

Avg. volume

3.7M

P/E ratio

-4.12

Altimmune, Inc. - Common Stock News